In my first two articles, I covered Hainan’s medical device import pathway and how Boao’s real-world data can accelerate NMPA registration. Now I want to examine the next logical step: manufacturing on the island. For foreign medtech companies that have tested the China market through Boao, or for those looking to establish a production base to serve the mainland, Hainan offers a set of incentives that change the traditional manufacturing calculus.
Why manufacture in Hainan rather than elsewhere in China?
The short answer is the convergence of three policies that no other Chinese province combines in the same way:
1. Duty‑free import of components, materials, and production equipment — anything brought into Hainan from abroad for manufacturing purposes enters with zero customs duty.
2. The 30% value‑add rule — if at least 30% of a finished device’s ex‑factory value is created on the island (including local labour, assembly, testing, packaging, and overhead), it can be sold into mainland China under Hainan origin, bypassing the standard import duties that would apply if the same device were shipped directly to Shanghai or Guangzhou.
3. Preferential tax treatment — a 15% corporate income tax rate for businesses in encouraged industries (medical device manufacturing qualifies) and a 15% personal income tax cap for high‑level talent, which helps attract the engineers and quality managers a medtech line requires.
For a foreign manufacturer, this means the landed cost of a "Made in Hainan" device sold to a mainland hospital can be significantly lower than importing a fully finished unit, even before factoring in logistics savings and faster market responsiveness.
What manufacturing actually looks like on the island
I am not seeing giant Medtronic‑scale factories yet. What is emerging is more targeted and pragmatic:
· Finishing and kitting lines. A European in‑vitro diagnostics company is establishing a reagent kitting and quality‑control operation in Haikou’s comprehensive bonded zone. Bulk reagents and antibodies arrive duty‑free, are aliquoted, labelled, and packaged, and the 30% threshold is met through local labour and testing. The finished kits then move to the mainland as Hainan‑origin products.
· Device assembly and calibration. A Japanese imaging equipment manufacturer is evaluating Hainan for final assembly of portable ultrasound systems. Components from Southeast Asia and Japan enter duty‑free, assembly and calibration are done locally, and the devices are shipped to mainland distributors under the preferential origin rule.
· Contract manufacturing partnerships. Some foreign SMEs are working with existing Hainan‑based contract manufacturers who already hold ISO 13485 certification, reducing the need for heavy upfront capital investment.
In each case, the model is not full‑scale manufacturing from scratch, but a targeted addition of value that crosses the 30% threshold while keeping investment manageable.
The checklist for a Hainan manufacturing project
The practical steps typically include:
1. Confirm that the device is on the encouraged industries catalogue to access the 15% CIT rate.
2. Model the 30% value‑add calculation — include components, labour, utilities, testing, packaging, and allocated overhead. This must be documented for customs.
3. Select a site — options include the Haikou Comprehensive Bonded Zone, Yangpu Economic Development Zone, or the Boao Lecheng zone if clinical integration matters.
4. Obtain NMPA production registration — if the device is already NMPA‑approved, the manufacturer must hold a production licence. If not, the Boao RWD pathway and eventual registration must be aligned with the manufacturing timeline.
5. Recruit skilled talent — technicians, quality engineers, regulatory specialists. The 15% IIT cap is a powerful recruiting tool, but competition for experienced medtech personnel is rising.
6. Manage cross‑border data — if the device involves software or connectivity, ensure compliance with China’s data security and personal information protection rules.
Where the friction remains
Manufacturing medical devices is highly regulated anywhere, and Hainan is no exception. GMP certification must be obtained from the Hainan MPA, and audit readiness is expected from day one. Some special components may need to be air‑freighted in at higher cost. And the 30% rule, while commercially attractive, requires rigorous documentation and a clear audit trail; “creative” accounting is not accepted.
Strategic takeaway
For foreign medtech companies that have already navigated NMPA registration — or are on a path to do so via Boao — Hainan manufacturing may be a good option. It is a near‑term operational decision that can improve margins, simplify mainland logistics, and create a stronger China presence. “Hainan origin” label also gibes the eligibility for public tendering processes in mainland hospitals.
In my next and final article in this series, I will turn to pharmaceuticals — where the Boao pathway also applies, but where the regulatory and manufacturing dynamics differ in important ways.
Author:
Ulla Nurmenniemi
Chairman, Wellbridge Ltd (Beijing & Haikou)
Vice Chairman, FinnCham China - Beijing
Submit Cancel